Mexico and Canada 
Outside North America 
US 
CAT #: 21010080
IGH Framework 3 (FR3) - Unlabeled for Gel Detection
Product Use
IGH Framework 3 (FR3) – Unlabeled for Gel Detection is a Research Use Only master mix that can be used to identify immunoglobulin heavy chain clonality.
Product Details
-
Description
Genes encoding immunoglobulin heavy chain (IGH) molecules are assembled from multiple polymorphic gene segments that undergo rearrangement and selection during B-cell development. Rearrangement of these variable (V), diversity (D), and joining (J) genetic segments result in VDJ products of unique length and sequence. Clonal IGH rearrangements can identified through analyses of the size distributions of DNA products amplified from conserved sequences that flank this region. For example, DNA isolated from a normal polyclonal population of B-cells generates a Gaussian distribution (bell-shaped size curve) of amplified products, whereas DNA amplified from a clonal B-cell population generates one or two product(s) of unique size(s) that reflect proliferation of a single rearranged clone.
This master mix amplifies gDNA, targeting the conserved Framework 3 (FR3) region of the IGH gene and the joining (JH) region. These regions flank the unique, hypervariable, antigen-binding, complementarity determining region 3 (CDR3). Clonality is indicated if the master mix generates clonal band(s). PCR products can be analyzed using standard gel electrophoresis using heteroduplex analysis with ethidium bromide staining.
Legal Notice
Warranty and Liability
Invivoscribe, Inc. (Invivoscribe®) is committed to providing the highest quality products. Invivoscribe® warrants that the products meet or exceed the performance standards described in the Instructions For Use, as to products with such an insert. If a product is covered by product specifications and does not perform as specified, our policy is to replace the product or credit the full purchase price. No other warranties of any kind, expressed or implied, are provided by Invivoscribe®. Invivoscribe® liability shall not exceed the purchase price of the product. Invivoscribe® shall have no liability for direct, indirect, consequential or incidental damages arising from the use, results of use, or inability to use its products; product efficacy under purchaser controlled conditions in purchaser’s laboratory must be established and continually monitored through purchaser defined and controlled processes including but not limited to testing of internally validated positive, negative, and blank controls every time a sample is tested. Ordering, acceptance and use of product constitutes purchaser acceptance of sole responsibility for assuring product efficacy and purchaser agreement to the limitation of liability set forth in this paragraph.
This product is for Research Use Only; not for use in diagnostic procedures.
©2020 Invivoscribe, Inc. All rights reserved. The trademarks mentioned herein are the property of Invivoscribe, Inc. and/or its affiliates, or (as to the trademarks of others used herein) their respective owners.